tetano
Editor, Senior Moderator
Sci Rep
. 2024 Apr 29;14(1):9854.
doi: 10.1038/s41598-024-60089-4. PASC (Post Acute Sequelae of COVID-19) is associated with decreased neutralizing antibody titers in both biological sexes and increased ANG-2 and GM-CSF in females
Ethan B Jansen[SUP] 1 2 [/SUP], Ali Toloue Ostadgavahi[SUP] 3 [/SUP], Benjamin Hewins[SUP] 3 [/SUP], Rachelle Buchanan[SUP] 1 [/SUP], Brittany M Thivierge[SUP] 1 [/SUP], Gustavo Sganzerla Martinez[SUP] 3 [/SUP], Una Goncin[SUP] 4 [/SUP], Magen E Francis[SUP] 1 2 [/SUP], Cynthia L Swan[SUP] 1 [/SUP], Erin Scruten[SUP] 1 [/SUP], Jack Bell[SUP] 1 2 [/SUP], Joseph Darbellay[SUP] 1 [/SUP], Antonio Facciuolo[SUP] 1 5 [/SUP], Darryl Falzarano[SUP] 1 5 [/SUP], Volker Gerdts[SUP] 1 5 [/SUP], Mark E Fenton[SUP] 6 [/SUP], Peter Hedlin[SUP] 4 [/SUP], David J Kelvin[SUP] 3 [/SUP], Alyson A Kelvin[SUP] 7 [/SUP]
Affiliations
Post-acute sequelae of COVID-19 (PASC) or the continuation of COVID-19 (Coronavirus disease 2019) symptoms past 12 weeks may affect as many as 30% of people recovering from a SARS-CoV-2 (severe acute respiratory coronavirus 2) infection. The mechanisms regulating the development of PASC are currently not known; however, hypotheses include virus reservoirs, pre-existing conditions, microblood clots, immune dysregulation, as well as poor antibody responses. Importantly, virus neutralizing antibodies are essential for COVID-19 recovery and protection from reinfection but there is currently limited information on these immune regulators and associated cytokines in PASC patients. Understanding the key drivers of general and specific symptoms associated with Long COVID and the presence of virus neutralizing antibodies in PASC will aid in the development of therapeutics, diagnostics, and vaccines which currently do not exist. We designed a cross-sectional study to investigate systemic antibody and cytokine responses during COVID-19 recovery and PASC. In total, 195 participants were recruited in one of four groups: (1) Those who never had COVID-19 (No COVID); (2) Those in acute COVID-19 recovery (Acute Recovery) (4-12 weeks post infection); (3) Those who recovered from COVID-19 (Recovered) (+ 12 weeks from infection); and (4) those who had PASC (PASC) (+ 12 weeks from infection). Participants completed a questionnaire on health history, sex, gender, demographics, experiences with COVID-19 acute and COVID-19 recovery/continuing symptoms. Serum samples collected were evaluated for antibody binding to viral proteins, virus neutralizing antibody titers, and serum cytokine levels using Ella SimplePlex Immunoassay™ panels. We found participants with PASC reported more pre-existing conditions (e.g. such as hypertension, asthma, and obesity), and PASC symptoms (e.g. fatigue, brain fog, headaches, and shortness of breath) following COVID-19 than COVID-19 Recovered individuals. Importantly, we found PASC individuals to have significantly decreased levels of neutralizing antibodies toward both SARS-CoV-2 and the Omicron BA.1 variant. Sex analysis indicated that female PASC study participants had sustained antibody levels as well as levels of the inflammatory cytokines GM-CSF and ANG-2 over time following COVID-19. Our study reports people experiencing PASC had lower levels of virus neutralizing antibodies; however, the results are limited by the collection time post-COVID-19 and post-vaccination. Moreover, we found females experiencing PASC had sustained levels of GM-CSF and ANG-2. With lower levels of virus neutralizing antibodies, this data suggests that PASC individuals not only have had a suboptimal antibody response during acute SARS-CoV-2 infection but may also have increased susceptibility to subsequent infections which may exacerbate or prolong current PASC illnesses. We also provide evidence suggesting GM-CSF and ANG-2 to play a role in the sex-bias of PASC. Taken together, our findings maybe important for understanding immune molecular drivers of PASC and PASC subgroups.
. 2024 Apr 29;14(1):9854.
doi: 10.1038/s41598-024-60089-4. PASC (Post Acute Sequelae of COVID-19) is associated with decreased neutralizing antibody titers in both biological sexes and increased ANG-2 and GM-CSF in females
Ethan B Jansen[SUP] 1 2 [/SUP], Ali Toloue Ostadgavahi[SUP] 3 [/SUP], Benjamin Hewins[SUP] 3 [/SUP], Rachelle Buchanan[SUP] 1 [/SUP], Brittany M Thivierge[SUP] 1 [/SUP], Gustavo Sganzerla Martinez[SUP] 3 [/SUP], Una Goncin[SUP] 4 [/SUP], Magen E Francis[SUP] 1 2 [/SUP], Cynthia L Swan[SUP] 1 [/SUP], Erin Scruten[SUP] 1 [/SUP], Jack Bell[SUP] 1 2 [/SUP], Joseph Darbellay[SUP] 1 [/SUP], Antonio Facciuolo[SUP] 1 5 [/SUP], Darryl Falzarano[SUP] 1 5 [/SUP], Volker Gerdts[SUP] 1 5 [/SUP], Mark E Fenton[SUP] 6 [/SUP], Peter Hedlin[SUP] 4 [/SUP], David J Kelvin[SUP] 3 [/SUP], Alyson A Kelvin[SUP] 7 [/SUP]
Affiliations
- PMID: 38684819
- DOI: 10.1038/s41598-024-60089-4
Post-acute sequelae of COVID-19 (PASC) or the continuation of COVID-19 (Coronavirus disease 2019) symptoms past 12 weeks may affect as many as 30% of people recovering from a SARS-CoV-2 (severe acute respiratory coronavirus 2) infection. The mechanisms regulating the development of PASC are currently not known; however, hypotheses include virus reservoirs, pre-existing conditions, microblood clots, immune dysregulation, as well as poor antibody responses. Importantly, virus neutralizing antibodies are essential for COVID-19 recovery and protection from reinfection but there is currently limited information on these immune regulators and associated cytokines in PASC patients. Understanding the key drivers of general and specific symptoms associated with Long COVID and the presence of virus neutralizing antibodies in PASC will aid in the development of therapeutics, diagnostics, and vaccines which currently do not exist. We designed a cross-sectional study to investigate systemic antibody and cytokine responses during COVID-19 recovery and PASC. In total, 195 participants were recruited in one of four groups: (1) Those who never had COVID-19 (No COVID); (2) Those in acute COVID-19 recovery (Acute Recovery) (4-12 weeks post infection); (3) Those who recovered from COVID-19 (Recovered) (+ 12 weeks from infection); and (4) those who had PASC (PASC) (+ 12 weeks from infection). Participants completed a questionnaire on health history, sex, gender, demographics, experiences with COVID-19 acute and COVID-19 recovery/continuing symptoms. Serum samples collected were evaluated for antibody binding to viral proteins, virus neutralizing antibody titers, and serum cytokine levels using Ella SimplePlex Immunoassay™ panels. We found participants with PASC reported more pre-existing conditions (e.g. such as hypertension, asthma, and obesity), and PASC symptoms (e.g. fatigue, brain fog, headaches, and shortness of breath) following COVID-19 than COVID-19 Recovered individuals. Importantly, we found PASC individuals to have significantly decreased levels of neutralizing antibodies toward both SARS-CoV-2 and the Omicron BA.1 variant. Sex analysis indicated that female PASC study participants had sustained antibody levels as well as levels of the inflammatory cytokines GM-CSF and ANG-2 over time following COVID-19. Our study reports people experiencing PASC had lower levels of virus neutralizing antibodies; however, the results are limited by the collection time post-COVID-19 and post-vaccination. Moreover, we found females experiencing PASC had sustained levels of GM-CSF and ANG-2. With lower levels of virus neutralizing antibodies, this data suggests that PASC individuals not only have had a suboptimal antibody response during acute SARS-CoV-2 infection but may also have increased susceptibility to subsequent infections which may exacerbate or prolong current PASC illnesses. We also provide evidence suggesting GM-CSF and ANG-2 to play a role in the sex-bias of PASC. Taken together, our findings maybe important for understanding immune molecular drivers of PASC and PASC subgroups.